Most Common Adverse Events (AEs) in Trulance Studies1
AE Trulance 3 mg
(n=863)
%
Placebo
(n=870)
%
Diarrhea 5 1
No additional AEs were reported in at least 2% of Trulance-treated patients, and at an incidence greater than placebo.
  • Severe diarrhea was reported in 0.6% of patients receiving 3 mg of Trulance vs 0.3% of placebo-treated patients
  • If severe diarrhea occurs, suspend dosing and rehydrate the patient

4% discontinuation rate for Trulance vs 2% for placebo1

  • 2% discontinuation rate due to diarrhea vs 0.5% for placebo

No drug-drug interactions occurred with Trulance1

  • Trulance therapy is minimally absorbed with negligible systemic availability